168 related articles for article (PubMed ID: 19544345)
1. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.
Barreca ML; Iraci N; De Luca L; Chimirri A
ChemMedChem; 2009 Sep; 4(9):1446-56. PubMed ID: 19544345
[TBL] [Abstract][Full Text] [Related]
2. Substituted 2-pyrrolinone inhibitors of HIV-1 integrase.
Dayam R; Al-Mawsawi LQ; Neamati N
Bioorg Med Chem Lett; 2007 Nov; 17(22):6155-9. PubMed ID: 17911021
[TBL] [Abstract][Full Text] [Related]
3. New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.
Ferro S; De Luca L; Barreca ML; De Grazia S; Christ F; Debyser Z; Chimirri A
Bioorg Med Chem; 2010 Aug; 18(15):5510-8. PubMed ID: 20630765
[TBL] [Abstract][Full Text] [Related]
4. Fully flexible low-mode docking: application to induced fit in HIV integrase.
Keserû GM; Kolossváry I
J Am Chem Soc; 2001 Dec; 123(50):12708-9. PubMed ID: 11741448
[No Abstract] [Full Text] [Related]
5. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
Johnson BC; Métifiot M; Pommier Y; Hughes SH
Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850
[TBL] [Abstract][Full Text] [Related]
6. Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.
Beare KD; Coster MJ; Rutledge PJ
Curr Med Chem; 2012; 19(8):1177-92. PubMed ID: 22214459
[TBL] [Abstract][Full Text] [Related]
7. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.
De Luca L; De Grazia S; Ferro S; Gitto R; Christ F; Debyser Z; Chimirri A
Eur J Med Chem; 2011 Feb; 46(2):756-64. PubMed ID: 21227550
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial.
Johnson AA; Marchand C; Pommier Y
Curr Top Med Chem; 2004; 4(10):1059-77. PubMed ID: 15193139
[TBL] [Abstract][Full Text] [Related]
10. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
Chen X; Tsiang M; Yu F; Hung M; Jones GS; Zeynalzadegan A; Qi X; Jin H; Kim CU; Swaminathan S; Chen JM
J Mol Biol; 2008 Jul; 380(3):504-19. PubMed ID: 18565342
[TBL] [Abstract][Full Text] [Related]
11. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.
Savarino A
Retrovirology; 2007 Mar; 4():21. PubMed ID: 17374162
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.
Hazuda DJ; Felock P; Witmer M; Wolfe A; Stillmock K; Grobler JA; Espeseth A; Gabryelski L; Schleif W; Blau C; Miller MD
Science; 2000 Jan; 287(5453):646-50. PubMed ID: 10649997
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation and molecular modeling studies of quinolonyl diketo acid derivatives: new structural insight into the HIV-1 integrase inhibition.
Vandurm P; Guiguen A; Cauvin C; Georges B; Le Van K; Michaux C; Cardona C; Mbemba G; Mouscadet JF; Hevesi L; Van Lint C; Wouters J
Eur J Med Chem; 2011 May; 46(5):1749-56. PubMed ID: 21385662
[TBL] [Abstract][Full Text] [Related]
14. Stabilization of the integrase-DNA complex by Mg2+ ions and prediction of key residues for binding HIV-1 integrase inhibitors.
Miri L; Bouvier G; Kettani A; Mikou A; Wakrim L; Nilges M; Malliavin TE
Proteins; 2014 Mar; 82(3):466-78. PubMed ID: 24038133
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors.
Jiang F; Chen W; Yi K; Wu Z; Si Y; Han W; Zhao Y
Clin Immunol; 2010 Dec; 137(3):347-56. PubMed ID: 20832370
[TBL] [Abstract][Full Text] [Related]
16. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.
Fikkert V; Van Maele B; Vercammen J; Hantson A; Van Remoortel B; Michiels M; Gurnari C; Pannecouque C; De Maeyer M; Engelborghs Y; De Clercq E; Debyser Z; Witvrouw M
J Virol; 2003 Nov; 77(21):11459-70. PubMed ID: 14557631
[TBL] [Abstract][Full Text] [Related]
17. Impact of resistance mutations on inhibitor binding to HIV-1 integrase.
Chen Q; Buolamwini JK; Smith JC; Li A; Xu Q; Cheng X; Wei D
J Chem Inf Model; 2013 Dec; 53(12):3297-307. PubMed ID: 24205814
[TBL] [Abstract][Full Text] [Related]
18. Homology model-guided 3D-QSAR studies of HIV-1 integrase inhibitors.
Sharma H; Cheng X; Buolamwini JK
J Chem Inf Model; 2012 Feb; 52(2):515-44. PubMed ID: 22256860
[TBL] [Abstract][Full Text] [Related]
19. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
[TBL] [Abstract][Full Text] [Related]
20. Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors.
Zhao XZ; Smith SJ; Maskell DP; Métifiot M; Pye VE; Fesen K; Marchand C; Pommier Y; Cherepanov P; Hughes SH; Burke TR
J Med Chem; 2017 Sep; 60(17):7315-7332. PubMed ID: 28737946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
